Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients
An Open-label, Concentration Controlled, Randomized, 12 Month Study of Prograf + Rapamune + Cor
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Age: 13 years or older, 40 kgs or more
- End-stage renal disease
- African-American/Black transplant recipient and/or repeat renal transplant recipient who lost a previous allograft
Exclusion Criteria
- Evidence of active infection
- Evidence abnormal chest x-ray
- Patients with HIV.
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Kidney Diseases
- Urologic Diseases
- Renal Insufficiency, Chronic
- Kidney Failure, Chronic
- Renal Insufficiency
- Graft vs Host Disease
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
Other Study ID Numbers
- 0468H1-101164
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplantation
-
NCT00189735CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, Renal
-
NCT01670058CompletedKidney Transplantation: Transplantation, Kidney
-
NCT02234349CompletedKidney Transplantation | Pancreas-kidney Transplantation
-
NCT02118896CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01614665CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01371344TerminatedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01371331CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT01655563CompletedLiver Transplantation | Kidney Transplantation | Heart Transplantation
-
NCT00461357UnknownKidney Function After Transplantation | Outcome After Kidney Transplantation
Clinical Trials on Rapamune
-
NCT00621101CompletedHypercholesterolemia | Pharmacokinetics | Immunosuppression | Drug Interactions
-
NCT07378657RecruitingOrbital Lymphatic Malformation
-
NCT04948203Active, not recruitingPulmonary Fibrosis | COVID-19 Pneumonia | Long COVID
-
NCT02509468CompletedVascular Malformation
-
NCT07359807Not yet recruitingSuperficial Femoral Artery Disease | Popliteal Artery Disease
-
NCT03933904Active, not recruitingCastleman Disease | Castleman's Disease, Multicentric
-
NCT06673290RecruitingLymphatic Malformation
-
NCT00975819CompletedTufted Angioma | Microcystic Lymphatic Malformation | Kaposiform Hemangioendotheliomas | Capillary Venous Lymphatic Malformation | Venous Lymphatic Malformation | Mucocutaneous Lymphangiomatosis and Thrombocytopenia | Capillary Lymphatic Arterial Venous Malformations | PTEN Overgrowth Syndrome With Vascular Anomaly | Lymphangiectasia Syndromes